Quality Improvement

   

Improving Amyloidosis Care Through Quality Improvement in Africa

  Amyloidosis Africa leads structured amyloidosis quality improvement in Africa to close the gap between clinical evidence and routine healthcare practice. Across many African health systems, clinicians encounter patients with unexplained heart failure, neuropathy, or systemic symptoms without recognizing amyloidosis as a potential diagnosis. Consequently, patients often experience years of misdiagnosis, delayed referrals, and fragmented care.   Quality improvement provides a practical and measurable strategy to address these gaps. Rather than focusing solely on awareness, we embed evidence-based improvements directly into real-world clinical workflows.  

Why Amyloidosis Quality Improvement Matters in Africa

  In many African countries, healthcare systems face resource constraints, high patient volumes, and competing priorities. As a result, rare diseases such as amyloidosis frequently remain under-recognized. Furthermore, inconsistent diagnostic pathways and limited access to advanced testing contribute to prolonged delays.   Studies globally show that patients with cardiac amyloidosis may wait several years before receiving an accurate diagnosis. In African settings, these delays can be even longer due to:

• Low clinical suspicion
• Limited availability of monoclonal protein screening
• Restricted access to nuclear imaging
• Fragmented referral systems

  Therefore, amyloidosis care improvement in Africa requires structured interventions that strengthen clinical pathways, improve referral systems, and enhance diagnostic accuracy.  

Our Approach to Quality Improvement in Amyloidosis

  Amyloidosis Africa designs and implements data-driven quality improvement initiatives embedded within heart failure and neurology services. Instead of operating as standalone projects, these initiatives integrate into existing clinical programs to ensure sustainability.   1. Identifying System Gaps We assess current diagnostic pathways within participating institutions, including referral patterns, time to diagnosis, and misclassification trends.   2. Strengthening Diagnostic Pathways We support the development of standardized diagnostic pathways for suspected cardiac and systemic amyloidosis, improving clarity and consistency across departments.   3. Embedding Education Into Practice We integrate clinician education into measurable quality improvement cycles, focusing on:

• Increased suspicion for ATTR-CM in heart failure clinics
• Improved documentation of red-flag symptoms
• Faster referral to specialists

  4. Measuring Impact and Outcomes We monitor key indicators such as diagnostic turnaround time, referral efficiency, and identification rates to ensure sustainable impact.  

Cardiac Amyloidosis Quality Improvement in Heart Failure Services

  Cardiac amyloidosis often presents as heart failure with preserved ejection fraction or unexplained hypertrophy. Without structured diagnostic prompts, clinicians may treat symptoms without identifying the underlying cause.   Through targeted quality improvement programs, we introduce:

• Structured red-flag checklists
• Standardized evaluation protocols
• Clear referral algorithms
• Interdisciplinary case discussions

  As a result, clinicians identify cases earlier and patients receive appropriate evaluation sooner.  

Strengthening Referral Pathways Across African Health Systems

  Quality improvement extends across the full care continuum. We work with institutions to strengthen referral networks between primary care, cardiology, neurology, and tertiary centers.   Improved referral systems reduce delays, duplication, and patient drop-off, supporting long-term system efficiency.  

Sustainability and Capacity Building

 

• Training local clinical champions
• Integrating tools into electronic medical records
• Developing institutional protocols
• Supporting multidisciplinary leadership

  This approach ensures that improvements are maintained beyond initial project implementation.  

Building a Culture of Continuous Improvement

  Amyloidosis quality improvement represents a shift toward continuous evaluation, data-driven practice, and collaborative care. By integrating research, education, and clinical implementation, we strengthen healthcare systems from within.   This leads to earlier diagnosis, improved clinical awareness, and better patient outcomes across African settings.  

Moving Forward

  Reducing delays in amyloidosis diagnosis requires coordinated and measurable action. Through structured quality improvement initiatives, we translate evidence into practice and improve real-world care delivery.   If your institution seeks to improve diagnosis, optimize referral pathways, or implement data-driven quality programs, we welcome collaboration.   Together, we can accelerate earlier diagnosis and improve outcomes for patients living with amyloidosis across Africa.    

OUR DOCUMENTS